The results of a large, retrospective study of the use of low-dose atropine drops used to slow progression of myopia in children today, JAMA Ophthalmology, send a mixed message about the safety of the drops. On the one hand, the findings show no difference in ocular complications such as glaucoma and cataracts between Taiwanese children treated with the drops and those who weren’t. On the other hand, there is the suggestion of greater risk with longer use of the drops. But to further complicate matters, the effect size diminished after adjusting the analysis to take into account high myopia, and cumulative exposure (as opposed to duration) was not associated with a greater risk of ocular complications.

“This study found that longer-term atropine prescription for myopia control was ass

See Full Page